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Background: Intramuscular injection of botulinum toxin type-A given by manual intramuscular needle placement
in the lower extremity under general anaesthesia is an established treatment and standard of care in managing
spasticity in children with spastic cerebral palsy. Optimal needle placement is essential. However, reports of
injection and verification techniques used in previous studies have been partly incomplete and there are
methodological shortcomings. This paper describes a detailed protocol for manual intramuscular needle placement
checked by passive stretching and relaxing of the target muscle for each individual muscle injection location in the
lower extremity during botulinum toxin type-A treatment under general anaesthesia in children with spastic
cerebral palsy. It explains the design of a study to verify this protocol, which consists of an injection technique
combined with a needle localizing technique, as by means of electrical stimulation to determine its precision.
Methods: Setting: University Medical Centre, Department of Paediatric Rehabilitation Medicine, the Netherlands.
Design: prospective observational study.
Participants: children with spastic cerebral palsy, aged 4 to 18 years, receiving regular botulinum toxin type-A
treatment under general anaesthesia to improve their mobility, are recruited from the Department of Paediatric
Rehabilitation Medicine at VU University Medical Centre, Amsterdam, the Netherlands.
Method: a detailed protocol for manual intramuscular needle placement checked by passive stretching and relaxing
of the target muscle has been developed for each individual muscle injection location of the adductor brevis
muscle, adductor longus muscle, gracilis muscle, semimembranosus muscle, semitendinosus muscle, biceps femoris
muscle, rectus femoris muscle, gastrocnemius lateralis muscle, gastrocnemius medialis muscle and soleus muscle.
This protocol will be verified as by means of electrical stimulation.
Technical details: 25 mm or 50 mm Stimuplex-needle and a Stimuplex-HNS-12 electrical stimulator will be used.
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Discussion: Botulinum toxin type-A injected in the intended muscle is expected to yield the greatest effect in
terms of activities. Protocols for manual intramuscular needle placement should be described in detail and verified
to determine its precision. Detailed and verified protocols are essential to be able to interpret the results of
botulinum toxin type-A treatment studies.
Keywords: Needle placement, Botulinum toxin type-A, Electrical stimulation, Children, Cerebral palsy, Spasticity, InjectionsBackground
Cerebral palsy (CP) is defined as a disorder of posture
and movement due to a defect or lesion in the immature
brain [1]. It causes physical and movement disability in
childhood with an annual incidence of 2 to 3 per 1000
live born children [1,2]. It is a non-progressive motor
disorder. The type of movement disorder is classified as
spastic, ataxic, dyskinetic, or a combination. To manage
spasticity in children with spastic cerebral palsy botulinum
toxin type-A (BTX-A) injected by manual intramuscular
needle placement in the lower extremity under general
anaesthesia is an established treatment and standard of
care in children with spastic CP [3-6].
BTX-A is produced by the bacterium Clostridium
botulinum, and blocks the release of acetylcholine at the
neuromuscular junction. This chemodenervation causes
temporary focal weakness of the injected muscle. Over a
period of weeks to months, collateral sprouting of the
nerve results in reinnervation of the muscle, which results
in recovery of the neuromuscular junctions [7-15].
There are various intramuscular injection techniques
and needle localizing techniques to administer BTX-A
treatment. Location of the needle after manual intramuscu-
lar needle placement can be checked by passive stretching
and relaxing of the target muscle (PSRM) [16-21], pal-
pation [18,21] and imaging and guiding tools: electrical
stimulation (ES) [16,18,21-23], ultrasound [19-21,23,24],
computer tomography, X-ray [14,16,17,19,22,24,25] and
electromyography [17,19,22].
PSRM is a rapid intramuscular needle localization
technique, useful for larger muscles, especially in the
lower extremity, which can be performed by one doctor
and one assistant without sophisticated equipment.
The selection of muscles to be injected depends on
the limitations the patient experiences in some activities
due to abnormal activation and activity of the muscles.
Injecting BTX-A at the correct location in the intended
muscle is expected to yield the greatest effect in terms
of activities. Therefore locating the right muscle is an
important part of the treatment. Protocols of intramuscu-
lar needle placement and intramuscular needle placement
verification techniques should be described in detail and
verified to determine its precision. Detailed and verified
protocols are essential to be able to interpret results of
BTX-A treatment studies.To evaluate previous research on this topic, the
literature was searched from the first relevant article
on this topic in 1994 to April 2013 using Pubmed,
Cochrane database and references of related articles.
Keywords used were needle placement, botulinum toxin
type-A, cerebral palsy, muscle, electrical stimulation,
children, spasticity, injections, echo and ultrasound.
MeSH headings used were botulinum toxin type-A, nee-
dle, cerebral palsy, muscle spasticity, children, injections,
muscle. All languages were included.
In a recent randomised controlled trial, two botulinum
toxin injection techniques were compared on the functional
improvement of the leg of children with CP. The efficacy
of BTX-A treatment was compared between intramuscular
injections guided by electrical stimulation and intramuscu-
lar injections guided by palpation. The treatment groups
received two weeks of physiotherapy after BTX-A treat-
ment. A third group received physiotherapy without
BTX-A treatment. The paper reported that intramuscular
injection of BTX-A guided by electrical stimulation plus
physiotherapy was likely to be best in terms of improving
functional performance and spasticity [18]. A similar study
compared “free hand” intramuscular needle placement
guided by anatomic landmarks, palpation and passively
stretching of the muscles with intramuscular needle
placement guided by electrical stimulation. “Free hand”
manual intramuscular needle placement was found to
be acceptable only for the gastrocnemius and soleus
muscles (75%) and unacceptable for all the other muscles
investigated [16]. A comparative study described intra-
muscular needle placement guided by ultrasound for
the gastrocnemius muscle. The accuracy of the manual
needle placement into the medial head was found to be
satisfactory, but the accuracy of the lateral head placement
was disappointing [21].
The present study describes a detailed protocol for
manual intramuscular needle placement in the lower
extremity checked by PSRM for each individual muscle
injection location during botulinum toxin type-A treat-
ment under general anaesthesia in children with spastic
cerebral palsy (see Additional file 1). It explains the de-
sign of a study to verify this protocol, which consists of
an injection technique combined with a needle localiz-
ing technique, as by means of ES and calculates its
precision.
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Methods
A detailed protocol for manual intramuscular needle
placement checked by PSRM has been developed for
each individual muscle and its injection locations of the
adductor brevis muscle (ADB), adductor longus muscle
(ADL), gracilis muscle (GR), semimembranosus muscle
(SEM), semitendinosus muscle (SET), biceps femoris
muscle (BF), rectus femoris muscle (RF), gastrocnemius
lateralis muscle (GL), gastrocnemius medialis muscle
(GM) and soleus muscle (SO) (see Additional file 1).
This protocol describes the origin, the insertion, the re-
lationship to other structures, the innervation and func-
tion of the muscle. It explains the start position of the
patient at physical examination for injection, how to
support and fixate the leg and the skills to localise the
muscle belly and the different injection locations of the
target muscle. It clarifies the direction of the needle, the
intramuscular needle placement technique and explains
the way to check the correct intramuscular needle loca-
tion by PSRM. It also shows needle placement hazards
for each muscle separately.
This protocol, which consists of a manual intramuscu-
lar needle placement technique combined with a needle
localizing technique, will be verified as by means of ES
to determine its precision.
Design
This is a prospective observational study.
Approval was obtained from the Medical Research
Ethics Committees of the Medical Centre, Amsterdam,
the Netherlands and MOVE Research Institute Amsterdam
of the VU University Medical Centre, Amsterdam, the
Netherlands. This study is in compliance with the Helsinki
Declaration. The research will be conducted according to
the 2004 version of the principles of the Declaration of
Helsinki and in accordance with the Dutch Medical Re-
search Involving Human Subjects Act (WMO). Risks asso-
ciated with participation and physical discomfort are very
small to negligible, and participation is not associated with
greater physiological discomfort compared to regular BTX-
A treatment [9,11,26-30].
Setting
University Medical Centre, Department of Paediatric
Rehabilitation Medicine, the Netherlands.
Participants
Children with spastic cerebral palsy, aged 4 to 18 years,
receiving regular BTX-A treatment under general an-
aesthesia to improve their mobility, will be recruited
from the Department of Paediatric Rehabilitation Medi-cine, VU University Medical Centre, Amsterdam, the
Netherlands.
Inclusion criteria:
1. Children aged 4 to 18 years
2. Diagnosis of spastic CP
3. Planned for regular BTX-A treatment under general
anaesthesia
4. Informed consent from caregivers and child if
capable
Exclusion criteria:
1. Risk > 2 of the American Society of Anesthesiologists
(ASA) physical status classification system during
anaesthesia
2. Previous surgery of the muscles included in the
study
3. Concomitant muscle-related diseases
4. Infection at the location of needle placement
Sample size calculation
Each individual muscle injection location of the ADB,
ADL, GR, SEM, SET, BF, RF, GL, GM and SO after man-
ual intramuscular needle placement checked by PSRM
will be investigated by ES to determine correct needle
placement.
The positive predictive value (PPV) or precision is
clinically the most relevant parameter to assess the value
of this manual intramuscular needle placement checked
by PSRM, as it indicates the proportion of the true posi-
tive needle placements in the intended muscle against
all, true and false, positive needle placements in the
intended muscle. If we assume that 90% of the test out-
come of manual intramuscular needle placements ob-
served after PSRM is determined to be positive, with
α = 0.05 and a power of 80%, then 41 observations of a
positive manual intramuscular needle placement will be
required for the injection location for each individual
muscle. If we assume that approximately 70% of the test
outcome of manual intramuscular needle placements
observed after PSRM is determined to be positive, with
α = 0.05 and a power of 80%, then a total of 60 observa-
tions of a positive manual intramuscular needle place-
ment will be required for the injection location for each
individual muscle.
Recruitment and consent
Patients with spastic CP aged 4 to 18 years, of both sexes,
treated at the Department of Paediatric Rehabilitation
Medicine, VU University Medical Centre, Amsterdam, the
Netherlands, will be recruited by their own doctor during
a consultation about regular BTX-A treatment. The care-
givers and the children will be given information about
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planation of the study by means of a cartoon, information
about insurance issues, an informed consent form and an
envelope to return the informed consent form will be
handed to the caregivers at the end of the consultation.
The participants will be given a telephone appointment at
least 48 hours before the BTX-A treatment, to answer any
questions they may have.
Study procedures
All children will receive their planned BTX-A treatment
under general anaesthesia in the operating rooms of the
VU University Medical Centre. The protocol for manual
intramuscular needle placement checked by PSRM will
be used (see Additional file 1).
A 25 mm or 50 mm Stimuplex needle will be used for
the injection. Manual intramuscular needle placement will
be assessed as a PSRM-positive verification when the nee-
dle moves upon passive stretching and relaxing of the in-
tended muscle. Manual intramuscular needle placement
will be defined as a PSRM-negative verification when there
is no movement or only a small straight movement of the
needle upon passive stretching and relaxing of the muscle
(see Figure 1). Whether or not the needle is positioned cor-




checked by passive stretching
and relaxing of the target muscle (PSRM)
Figure 1 Flowchart for the protocol for manual intramuscular needle
placement checked by PSRM will be assessed as a PSRM-positive verificatio
placement will be defined as a PSRM-negative verification when there is no
upon PSRM.The needle location will then be verified by means of a
Stimuplex HNS 12 electrical stimulator. ES will be initi-
ated at 1.50 mA. A palpable and visible contraction of
only the target muscle will be assessed as an ES-true
verification. The ES level will be reduced to 1.00 mA if
more than one muscle contracts at the same time. If
only the target muscle shows a palpable and visible con-
traction after the ES level is reduced, the needle location
will be defined as an ES-true verification. Contraction of
a different muscle will be assessed as ES-false verifica-
tion. When there is no contraction at all, the current will
be increased to a maximum of 5.0 mA. If there is still no
muscle contraction or a different muscle contracts, or
many muscles contract at the same time, this will be de-
fined as an ES-false verification. A palpable and visible
contraction of only the target muscle is defined as an
ES-true verification (see Figure 2). After this procedure,
regular BTX-A treatment will be continued and the nee-
dle can be readjusted if necessary.
All data will remain anonymous, to everyone except
the principal investigator.
Statistical analysis
Analyses will be performed using the Statistical Package
for the Social Sciences, version 15.0 (SPSS, IBM, Newamuscular 
lacement
needle does not move or
needle moves straight
PSRM-negative verification
placement checked by PSRM. Manual intramuscular needle
n when the needle moves upon PSRM. Manual intramuscular needle
movement or only a small straight movement of the needle
after manual intramuscular 
needle placement 
checked by PSRM 
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contraction of several 




















Figure 2 Flowchart for the protocol for manual intramuscular needle placement checked by PSRM as verified by means of ES. Whether
or not the needle is positioned correctly after manual intramuscular needle placement checked by PSRM; the needle at this stage will not be
removed or repositioned. ES will be initiated at 1.50 mA. A palpable and visible contraction of only the target muscle will be assessed as an
ES-true verification. The ES level will be reduced to 1.00 mA if more than one muscle contracts at the same time. If only the target muscle shows
a palpable and visible contraction after the ES level is reduced, the needle location will be defined as an ES-true verification. Contraction of a
different muscle will be assessed as ES-false verification. When there is no contraction at all, the current will be increased to a maximum of
5.0 mA. If there is still no muscle contraction or a different muscle contracts, or many muscles contract at the same time, this will be defined as
an ES-false verification.
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contingent table of manual intramuscular needle place-
ment checked by PSRM observations versus the corre-
sponding verification as by means of ES observations
(see Table 1). This table will be used to calculate the
positive predictive value (PPV), with its confidence inter-
val of 95%, as the main objective for each individual
muscle and muscle injection location. Positive predictive
value or precision is defined as the proportion of the
PSRM true positive observations against all the positive
observations, both PSRM true positive and PSRM obser-
vations. A PPV of 80% with 95% confidence interval and
a lower bound of 70% is defined as a minimal acceptable
proportion. In addition, negative predictive value (NPV),Table 1 Contingent table of manual intramuscular needle pla
corresponding observations with ES
Protocol for manual intramuscular needle
placement checked by PSRM
PSRM-positive
PSRM-negative
This table will be used to calculate the positive predictive value (PPV), with its confi
muscle injection location. The positive predictive value or precision is defined as th
positives and false positives. In addition, negative predictive value (NPV), sensitivitysensitivity and specificity will also be computed, with
their confidence intervals of 95%.
The measures of association (odds ratios) will be com-
pared with Cochran’s test for homogeneity. Factors which
might be related to a false positive intramuscular needle
placement checked by PSRM, such as type of target
muscle, injection location in the different target muscles,
left and right legs, gender, height, weight, body mass
index, age and level of experience of the doctor will be
assessed by means of a multifactorial analysis of variance.
Discussion
Botulinum toxin type-A injected in the intended muscle
is expected to yield the greatest effect in terms ofcement checked by PSRM observations versus the
Electrical stimulation
ES-true ES-false
True positive False positive PPV or precision
True negative False negative NNP
Sensitivity Specificity Accuracy
dence interval of 95%, as the main objective for each individual muscle and
e proportion of true positive results against all the positive results, both true
and specificity will also be computed, with their confidence intervals of 95%.
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placement should be described in detail and verified to
determine the precision of the injection method. De-
tailed and verified protocols are essential to be able to
interpret the results of botulinum toxin type-A treat-
ment studies.
Three relevant articles reporting specific on intramus-
cular needle placement in live humans failed to provide
detailed descriptions of a protocol for intramuscular in-
jection for each individual muscle injection location
[16,18,21].
In a randomized control trial two BTX-A intramuscu-
lar injection techniques were compared on the func-
tional improvement of the leg of children with CP. The
efficacy of BTX-A treatment was compared between
intramuscular injections guided by electrical stimulation
and intramuscular injections guided by palpation. The
statistical analysis of all intramuscular injections of one
group were merged [18]. According to the International
Classification of Functioning, Disability and Health for
Children and Youth (ICF-CY) spasticity of the muscle
(body structure) can impair function, which can cause
limitations of activities and participation in daily life.
There are many factors as health condition, environmental
and personal factors which also influence these functional,
activity and participation outcomes. Clinical outcomes are
blurred by all the factors described above so this methodo-
logical choice obscures the results. When there is no clear
description of a detailed and verified protocol for intra-
muscular needle placement merging of intramuscular in-
jections during analysis is not acceptable.
In an other article the author merged data of manual
intramuscular needle placements of the soleus muscle
and the gastrocnemius muscle and concluded that the
percentage of true positive manual needle placements
out of all positive needle placements checked by ES was
acceptable [16]. Combining muscles and muscle loca-
tions does not provide any useful information and does
not allow making conclusions about precision or accur-
acy of manual intramuscular needle placement and veri-
fication techniques.
Clarifying statistical terms used in a manuscript is of
great importance to make a clear interpretation of the
results. In this study protocol the main object of analysis
will be the contingent table of intramuscular needle
placement checked by PSRM observations versus the
corresponding observations with ES (see Table 1). This
table will be used to calculate the precision or PPV
which is defined as the proportion of true positive nee-
dle placements against all positive needle placement re-
sults (both true positives and false positives). During
BTX-A treatment, BTX-A should be injected only after
manual intramuscular needle placement checked posi-
tive by PSRM, ES or echo using a verified protocol.In this study protocol the statistical term accuracy is
defined as the proportion of true needle placements
(both true positives and true negatives). In a similar art-
icle the authors calculated the accuracy which was de-
fined differently as the proportion of positive needle
placements checked by ES out of all manual intramuscu-
lar injections. Negative manual intramuscular needle
placements were not investigated and not checked by ES
[16]. One article described intramuscular needle place-
ment based on only landmarks and palpation and in a
randomized clinical trial needle placement was based on
palpation of the muscle belly after increasing muscle
tone by stretching the spastic ankle plantar flexors. Both
studies did no use a PSRM technique or an other verifica-
tion technique to localize the correct needle placement in
the target muscle [18,21]. The three methodological
methods used do not allow the construction of a contin-
gent table of intramuscular needle placements checked by
a needle location technique observations versus observa-
tions verified as by means of ES or echo. Nor do they
allow the calculation of positive predictive values or preci-
sion with their confidence intervals as the main objective
for each individual muscle and muscle injection location
neither the calculation of the negative predictive value,
sensitivity and specificity. This obscures the outcome and
allows no clear answer to the question whether intramuscu-
lar needle placement is precise for a specific target muscle
and a specific injection location.
Additional file 1 provides no guidance of manual intra-
muscular needle placement depth because it is complicated.
The recruited children are aged between 4 and 18 years old
and needle depth might depend on the child, age, muscle
type, muscle injection location, left and right legs, gender,
height, weight and body mass index.
This protocol for manual intramuscular needle place-
ment checked by PSRM is described in detail. If verifica-
tion of this protocol as by means of ES shows a minimal
precision or PPV of 80% with 95% confidence interval
and a lower bound of 70% then this protocol is precise
and suitable for use in clinical practice of BTX-A treat-
ment in children with spastic cerebral palsy in the lower
extremity.
Additional file
Additional file 1: Descriptive protocol for manual intramuscular
needle placement checked by passive stretching and relaxing of
the target muscle. This file describes a detailed protocol for manual
intramuscular needle placement checked by passive stretching and
relaxing of the target muscle (PSRM) to determine correct needle
placement for each individual muscle injection location during botulinum
toxin type-A treatment under general anaesthesia in children with spastic
cerebral palsy for the adductor brevis muscle, adductor longus muscle,
gracilis muscle, semimembranosus muscle, semitendinosus muscle,
biceps femoris muscle, rectus femoris muscle, gastrocnemius lateralis
muscle, gastrocnemius medialis muscle and soleus muscle. Manual
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verification when the needle moves upon passive stretching and relaxing
of the intended muscle. Manual intramuscular needle placement will be
defined as a PSRM-negative verification when there is no movement or
only a small straight movement of the needle upon passive stretching
and relaxing of the muscle. For each muscle separately this protocol
describes the origin, the insertion, the relationship to other structures, the
innervation and function of the muscle. It explains the start position of
the patient at physical examination for injection, how to support and
fixate the leg and the skills to localise the muscle belly and the different
injection locations of the target muscle. It clarifies the direction of the
needle, the intramuscular needle placement technique and explains the
way to check the correct intramuscular needle location by passive
stretching and relaxing of the target muscle. It also shows needle
placement hazards for each muscle separately.
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